Enrollment Reaches 230+ in Halneuron Phase 2b; Top-Line Data Expected This Fall

What happened

Dogwood announced enrollment of more than 230 patients in its Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain, exceeding the original target of approximately 200 patients. The company reiterated that top-line data is expected later this fall, consistent with prior guidance pointing to Q3 2026. This progress follows earlier interim data showing separation versus placebo and low dropout rates, but it does not address the financing overhang detailed in the February 2026 DeepValue report. Investors still await resolution of the March 2026 warrant-issuance vote and subsequent cash runway disclosures, which were the primary catalysts for the WAIT rating. Without confirmation of funding through the data readout, the enrollment milestone alone is insufficient to remove the capital-structure risk.

Implication

Investors should not misinterpret the enrollment update as a derisking event; the Halneuron trial is on track, but the company's ability to fund through the readout is still uncertain. The >230 enrollment exceeds the original target, which could improve statistical power, but top-line timing is still 'later this fall,' leaving room for slippage. Without news on the March warrant vote or subsequent financing, the risk of further dilution or a cash crunch before the readout remains. The going-concern language from the Q3 2025 10-Q has not been retracted in this news, so investors must verify post-financing cash runway in the next quarterly filing. A prudent approach is to wait for confirmation of funding capacity through the top-line date before building a position, especially given the structural CVR and IP-control overhangs.

Thesis delta

The core thesis remains WAIT; enrollment progress is positive but does not change the financing-driven risk profile. The key catalysts remain cash runway and warrant exercise outcomes, which are not clarified by this news. Until the company demonstrates adequate funding through top-line data, the WAIT rating stands.